CHRS Stock Recent News

CHRS LATEST HEADLINES

CHRS Stock News Image - seekingalpha.com

Coherus Oncology, Inc. (NASDAQ:CHRS ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Bryan J. McMichael - Chief Financial Officer Dennis M.

seekingalpha.com 2025 Aug 09
CHRS Stock News Image - fool.com

Coherus (CHRS) Q2 Revenue Jumps 10%

fool.com 2025 Aug 07
CHRS Stock News Image - zacks.com

Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.14 per share a year ago.

zacks.com 2025 Aug 07
CHRS Stock News Image - globenewswire.com

– LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.

globenewswire.com 2025 Aug 07
CHRS Stock News Image - globenewswire.com

REDWOOD CITY, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Coherus, Coherus Oncology or the Company, Nasdaq: CHRS), today announced that its second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025. Starting at 5:00 p.m. EDT on August 7, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

globenewswire.com 2025 Jul 31
CHRS Stock News Image - seekingalpha.com

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer Theresa LaVallee - Chief Scientific & Development Officer Rosh Dias - Chief Medical Officer Sameer Goregaoker - Executive Vice President, Commercial Bryan McMichael - Chief Financial Officer Conference Call Participants Kripa Devarakonda - Truist Securities Brian Cheng - JPMorgan Mike Nedelcovych - TD Cowen Colleen Kusy - Baird Douglas Tsao - H.C. Wainwright Operator Good day and thank you for standing by.

seekingalpha.com 2025 May 12
CHRS Stock News Image - zacks.com

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.

zacks.com 2025 May 12
CHRS Stock News Image - globenewswire.com

– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025  – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.

globenewswire.com 2025 May 12
CHRS Stock News Image - globenewswire.com

REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

globenewswire.com 2025 May 05
CHRS Stock News Image - globenewswire.com

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming conferences:

globenewswire.com 2025 May 01
10 of 50